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http://dx.doi.org/10.10injury in combatants returning from the battlefield. The considerable evidence pointing at the accu-
mulation of tau aggregates and its recognition as a risk factor in neurodegenerative conditions such as
Alzheimer’s disease have led to a major effort to develop selective tau ligands that would allow
research into the physiopathologic underpinnings of traumatic brain injury and chronic traumatic en-
cephalopathy in military personnel and the civilian population. These tracers will allow new insights
into tau pathology in the human brain, facilitating research into causes, diagnosis, and treatment of
traumatic encephalopathy and major neurodegenerative dementias, such as Alzheimer’s disease and
some variants of frontotemporal lobar degeneration, in which tau plays a role. The field of selective
tau imaging has to overcome several obstacles, some of them associated with the idiosyncrasies of tau
aggregation and others related to radiotracer design. Aworldwide effort has focused on the develop-
ment of imaging agents that will allow selective tau imaging in vivo. Recent progress in the develop-
ment of these tracers is enabling the noninvasive assessment of the extent of tau pathology in the
brain, eventually allowing the quantification of changes in tau pathology over time and its relation
to cognitive performance, brain volumetrics, and other biomarkers, as well as assessment of efficacy
and patient recruitment for antitau therapeutic trials.
 2014 The Alzheimer’s Association. Published by Elsevier Inc. All rights reserved.Keywords: Alzheimer’s disease; Chronic traumatic encephalopathy; Tau; Tauopathies; Molecular neuroimaging; Neurode-generation; Radiotracer design1. Introduction
Tauopathies is the term used to describe a group of neurode-
generative conditions characterized by the pathologic accumu-
lation of tau aggregates in the brain. Along with Alzheimer’s
disease (AD) and some variants of frontotemporal lobe degen-
eration (FTLD), other tauopathies include Down’s syndrome,
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16/j.jalz.2014.04.013dementia with parkinsonism linked to chromosome-17
(FTDP-17), progressive supranuclear palsy (PSP), corticobasal
degeneration (CBD), and chronic traumatic encephalopathy
(CTE) [1–5]. Although all these conditions share tau
immunoreactivity in postmortem analysis, they can be
composed of different tau isoforms and show distinct
histopathologic and ultrastructural differences [2,6].
AD is the leading cause of dementia in the elderly, ac-
counting for 50% to 70% of dementia cases [7], whereas
FTLD is responsible for 10% to 20% of cases [8,9]. In AD,
the typical macroscopic picture is gross cortical atrophy.
Microscopically, there are widespread cellular degeneration
and diffuse synaptic and neuronal loss, accompanied by
reactive gliosis and the presence of the pathologic hallmarks
of the disease: extracellular b-amyloid (Ab) plaques and
intraneuronal bundles of hyperphosphorylated tau
aggregates [10–12]. In AD, these tau deposits can bey Elsevier Inc. All rights reserved.
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and neuropil threads, as well as dystrophic neurites in senile
plaques, whereas ultrastructurally, they aggregate in paired
helical filaments (PHFs) [2,5,13].
CTE is considered to be a slowly progressive tauopathy
associated with repetitive (concussive and subconcussive)
brain trauma, prevalent among contact sports athletes, phys-
ical abuse victims, and military personnel victim to blasts
and other injuries in the battlefield [4,14,15]. CTE is
clinically characterized by progressive cognitive decline
affecting memory and executive function, as well as
depression, higher impulsivity and aggressiveness, speech
and gait abnormalities, suicidal ideation, parkinsonism,
and dementia [16]. Neuropathologically, CTE is distin-
guished by cerebral atrophy, a fenestrated cavum septum pel-
lucidum, atrophy of the hippocampus, brainstem, and
mammillary bodies, and tau inclusions [4]. In CTE, in
contrast with other tauopathies, NFTs are observed mainly
in superficial cortical layers with a tendency to cluster around
deep sulci and involvement of astrocytes [16]. In several
cases, transactive response DNA-binding protein 43 (TDP-
43) inclusions and Ab plaques are also present [17].
Tau is found bound to tubulin to stabilize microtubules,
which are critical for the axonal support of neurons. Based
on the number of tubulin-binding repeats found on the tau
protein, six isoforms have been identified [18]. Although
the underlying mechanisms leading to tau hyperphosphory-
lation, misfolding, and aggregation remain unclear, tau
aggregation and deposition follows a stereotyped spatio-
temporal pathway both at the intraneuronal level [19,20]
and in its topographic and neuroanatomic distribution in
the brain [5,21–24]. Furthermore, mutations within the tau
gene (MAPT) have been shown to lead to FTDP-17 [25],
providing solid evidence that tau malfunction triggers neuro-
degeneration and dementia.
Although the prevalent etiologic hypothesis for AD pos-
tulates that either misprocessing of the amyloid precursor
protein or disruption of its clearance leads to the accumula-
tion of Ab in the brain in the form of plaques [26], human
postmortem studies have shown that it is the density of
NFTs and not of Ab insoluble plaques that strongly corre-
lates with neurodegeneration and cognitive deficits
[27–32]. Concurring with the postmortem studies, Ab
burden as assessed by positron emission tomography
(PET) does not strongly correlate with cognitive
impairment in AD patients [33,34]. Moreover, although
age-related limbic NFTs are frequently present in cogni-
tively unimpaired individuals, neocortical NFTs are much
less prevalent, in contrast with neocortical Ab plaques,
which appear abundantly in some nondemented individuals
[33,35–39]. The lack of a strong association between Ab
deposition and measures of cognition, synaptic activity,
and neurodegeneration in AD, in addition to the evidence
of Ab deposition in a high percentage of asymptomatic
healthy controls, points to the involvement of other
downstream mechanisms, such as tau aggregation andNFT formation, leading to synaptic failure and eventually
neuronal loss, indicating that Ab is an early and necessary,
though not sufficient, cause for cognitive impairment in
AD [40]. The fact that tau plays a key role in neurodegener-
ation [25,41–43] has led to the development of disease-
specific therapeutic strategies aimed at either inhibiting tau
hyperphosphorylation or aggregation or seeking direct stabi-
lization of microtubules [44–52].
In this context, there is a need to develop reliable diag-
nostic and prognostic biomarkers that can identify incipient
focal or diffuse pathology that will allow, when available,
early therapeutic interventions. Definitive diagnosis of these
neurodegenerative diseases can only be established by ex-
amination of the human brain at autopsy. Molecular imaging
procedures are suited to overcome the need for a neuropath-
ologic examination to identify the underlying pathology of
these diseases. The last two decades have been focused on
developing novel Ab ligands for the noninvasive detection
of Ab deposition in the brain [33,53]. Among these tracers,
2-(1-{6-[(2-[18F]fluoroethyl)(methyl)amino]-2-naphthyl}et-
hylidene)malononitrile (18F-FDDNP) was the only one
reported to bind to not only Ab deposits but also NFTs
[54]. Therefore, a selective and specific tau imaging agent
will be necessary to achieve a more profound understanding
of the pathophysiology of AD, CTE, FTLD, and other neuro-
degenerative conditions in which tau plays a role. The devel-
opment of a selective tau imaging agent will also lead to
improvements in differential diagnostic accuracy while
accelerating treatment discovery and monitoring of thera-
peutics.2. The idiosyncrasies of tau deposition
Tau is normally phosphorylated, and the degree of phos-
phorylation determines its binding to microtubules. The hy-
perphosphorylation of tau leads to weaker microtubule
binding [55] and an increase of unbound phospho-tau con-
centration in the cytosol. Hyperphosphorylated tau migrates
from the axonal compartment to the somatodendritic
compartment [56] where its accumulation leads to the for-
mation of the pathologic tau aggregates in the form of fila-
mentous inclusions [57], found in neurons, astrocytes, and
oligodendroglia [58].
There are several obstacles to be surmounted to be able to
image tau deposits [59]. In contrast toAb, most tau aggregates
are intracellular. Furthermore, there are six isoforms of tau,
and different combinations of these isoforms are manifested
as different clinical phenotypes [60,61]. To complicate
matters, tau aggregates are subjected to a wide spectrum of
posttranslation modifications such as phosphorylation,
nitration, acetylation, glycosylation, truncation, prolyl-
isomerization, glycation, ubiquitination, and so forth [62]
that, in addition to the combination of different isoforms,
lead to diverse ultrastructural conformations and typical path-
ologic lesions [2,6,63,64]. Another obstacle to be overcome
by selective tau tracers is the coexistence of other misfolded
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the case of AD in which tau and Ab are both colocalized in
gray matter areas. This issue is further complicated by the
much lower brain concentrations of tau than Ab and
aggregates in AD, where the concentrations of tau are,
depending on the brain region, w5 to 20 times lower than
those of Ab [65,66], requiring a radiotracer with high
selectivity for tau over Ab to be successful in AD.
These particular characteristics of tau deposition affect
the design of selective tau tracers. For example, the intracel-
lular location of tau aggregates means that a neuroimaging
radiotracer has to be able to cross not only the blood-brain
barrier (BBB) but also the cell membrane to reach its target,
imposing certain constraints in tracer design in terms of lip-
ophilicity and molecular size.3. Radiotracer design
Useful neuroimaging probes are required to fulfill a num-
ber of key general properties: they should be nontoxic lipo-
philic molecules of low molecular weight (,450) that
readily cross the BBB, with rapid clearance from blood and
preferably not metabolized, and with low nonspecific bind-
ing while reversibly binding to its target in a selective and
specific fashion [67–70]. It is also desirable that these
novel tau tracers are labeled with isotopes with longer half-
lives, such as fluorine 18 (18F; half-life of w2 hours), that
allow centralized production and regional distribution, as is
practicedworldwide in the fluorodeoxyglucose (18FDG) sup-
ply. Among the aforementioned properties, binding affinity
and lipophilicity are themost crucial for in vivo radioligands.
Most successful neuroimaging radiotracers show an initial
brain uptake above 5% of the injected dose at 2 to 5 minutes
after intravenous injection [69]. This brain initial tracer up-
take depends on several factors such as cerebral regional
blood flow, plasma radiotracer concentration, BBB perme-
ability, free fractions of the radiotracer in plasma and brain,
and so forth [69]. Ideally, tracers with LogPOCT values be-
tween 0.9 and 3.0 are sufficiently lipophilic to adequately
cross the BBB [71]. Within this ideal range, although more
lipophilic radioligands will display faster accumulation of
radioactivity in the brain than less lipophilic ones, they will
also be bound by plasma proteins and usually undergo fast
metabolism, leading to lower central nervous system uptake.
Exquisite selectivity is required for a tau radioligand. The
selectivity required for a particular neuroimaging radiotracer
depends on the concentration of available binding sites [68].
As mentioned before, in AD, there are higher cortical con-
centrations of Ab than PHF tau. Although in vitro reports
have already shown that based on affinity alone, a 3- to
30-fold selectivity for PHF tau is attainable [72–77],
simulation studies estimate that a 20- to 50-fold selectivity
for PHF tau over Ab will be required to image PHF tau
in vivo [78]. In addition to the initial assessment of safety,
brain kinetics, and tracer metabolism, the evaluation of tau
tracer selectivity in vivo poses some challenges. In the eval-uation of novel neuroreceptor radiotracers, competition and/
or displacement studies are used to ascertain selectivity and
specificity of the binding. The relatively high density of
aggregated tau in the brain requires micromolar concentra-
tions of an unlabeled competitor to effectively compete or
displace the tau radioligand, and untoward toxic effects are
likely at those high doses. Therefore, validation of tau tracer
selectivity relies on comparison of the regional distribution
of the tracer in both controls and pathologic cases in parallel
with other tracers that while sharing the property of binding
to b sheet conformation have been shown to have selective
binding to a different aggregated protein such as Ab or a-
synuclein, as well as comparison to the known regional brain
distribution of tau aggregates amassed from neuropathologic
studies of individuals with the same pathology. Further vali-
dation requires relating the binding of the tracer to clinical
measures of cognitive impairment or to biomarkers such as
gray matter atrophy, cerebrospinal fluid or plasma analytes,
or cerebral glucose metabolism known to be directly
affected by or correlated to tau deposition. The ultimate vali-
dation is attained by direct comparison of the regional distri-
bution of tau as assessed antemortem by PET and the tau
regional distribution assessed postmortem at autopsy.4. Tau imaging tracers
The achievement of Ab imaging with Pittsburgh com-
pound B (PiB) [79] led to a renewed international effort to
develop selective tau radiotracers. Given that the ultrastruc-
tural form that tau aggregates adopt in AD is PHF, most of
the efforts for developing selective tau imaging radiotracers
are focused on PHF tau. It is not clear at this stage if or
how well these tracers recognize the other conformations of
tau aggregates present in non-AD tauopathies. Although
most of the proposed novel PHF tau imaging tracers in recent
years originated from research groups working on therapeutic
tau antiaggregation or defibrillization agents [72,80–82], the
most successful attempts come from research groups
concentrated on screening available or novel chemical
libraries to identify potential high-affinity selective PHF tau
compounds that might be amenable to radiolabeling [83–85].
Several strategies for developing tau imaging agents have
been proposed. Based on the structure-activity relationship
(SAR) of N0-benzylidene-benzohydrazides and their fluores-
cent staining profile and antiaggregating activity, it has been
proposed that higher PHF tau selectivity can be attained by
incorporating bulky hydrophilic groups, which prevent bind-
ing to Ab fibrils, into these amphiphilic ligands [80].
Another group, also using SAR and tracer docking simula-
tion studies as a way to address differences in protein
composition and structural polymorphism, is proposing to
achieve PHF tau selectivity of 2-aryl benzothiazole deriva-
tives by altering the side chain composition of the com-
pounds [72,86]. A group focused on PHF tau therapeutics
[50,87] assessed different imidazothiazole, benzothiazole,
and pyrimidazole derivatives in primuline displacement
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transgenic mouse brains [81]. One of these derivatives,
SKT04-137, was radiolabeled with 18F for biodistribution
studies in mice, in which it showed sufficient brain uptake
but slow clearance from the brain (2 minute-to-60 minute ra-
tio of 2.9) [81]. A series of thiohydantoin [88], oxindole [89],
and styrylbenzimidazole [90] derivatives were designed and
synthesized for the detection of tau pathology. Preclinical
evaluation of these compounds showed that although all of
them displayed somewhat high affinity for NFT in autoradio-
graphic studies, only one of the styrylbenzimidazole deriva-
tives presented with sufficient entry into the brain [90].
Several other scaffolds (e.g., bis(arylvinyl)pyrazines,
-pyridazines, and -pyrimidines) have been proposed as po-
tential tau and Ab imaging agents [91].4.1. 18F-FDDNP
The first reported human amyloid imaging tracer with
nanomolar affinity to Ab fibrils [92] was 18F-FDDNP
(Fig. 1), a radiofluorinated 6-dialkylamino-2-naphthy
ethylidene derivative developed, synthesized, and character-
ized by Barrio et al. at University of California, Los Angeles
[93]. 18F-FDDNP was reported to bind to both the extracel-
lular Ab plaques and the intracellular NFT in AD [94,95]
18F-FDDNP was used to obtain the first human PET
images of Ab in an 82-year-old woman with AD, in whomFig. 1. Chemical structure of currently available tau radiotraceit showed a differential tracer clearance in different areas
of the brain, being slower in areas of Ab and tau deposition,
as pathologically confirmed later at autopsy [92,95]. In a
follow-up study, AD patients again demonstrated higher
accumulation and slower clearance of 18F-FDDNP than con-
trols in brain areas such as the hippocampus [94]. Retention
time of 18F-FDDNP in these brain regions was correlated
with lower memory performance scores in patients with
AD [96]. These findings were further confirmed in a larger
series in which AD and mild cognitive impairment (MCI)
participants were successfully differentiated from those
with no cognitive impairment [97]. 18F-FDDNP was also
used in the assessment of adult Down syndrome patients
[98] and football players suspected of CTE [99]. In a non-
AD tauopathy such as PSP [99], the retention pattern of
18F-FDDNP in subcortical and midbrain regions followed
the known distribution of tau pathology in PSP [100]. It
has been shown that 18F-FDDNP also binds prion plaques
in Creutzfeldt-Jakob disease [101] and Gerstmann-
Straussler-Scheinker disease [102]. Independent direct com-
parison of 18F-FDDNP with 11C-PIB in monkeys [103] and
human subjects highlighted the very limited dynamic range
of 18F-FDDNP [104,105]. 18F-FDDNP still remains the only
amyloid tracer showing retention in the medial temporal
cortex of AD patients, suggesting higher binding affinity
of FDDNP to NFT than to Ab [105]. However, in vitro eval-
uation of FDDNP in concentrations similar to those achievedrs. Most of them have been evaluated in clinical studies.
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Ab plaques [106]. The lack of selectivity of FDDNP for tau
might preclude its use in most cases requiring the identifica-
tion of the misfolded protein responsible of a specific pheno-
type.
4.2. 11C-lansoprazole
The benzimidazole derivatives lansoprazole and astemi-
zole, based on their in vitro ability to bind Ab and recombi-
nant tau fibrils, as well as PHF tau isolated from AD brains,
were also proposed as potential PHF tau imaging agents
[107]. A derivative of lansoprazole, N-methyl-lansoprazole
(Fig. 1), with a low nanomolar affinity for tau fibrils was ra-
diolabeled with 11C [108] and tested in mice and nonhuman
primates [77]. The initial studies in mice showed no entry of
the tracer into the brain, an effect that was reversed by inhib-
iting the permeability-glycoprotein 1 transporter with cyclo-
sporine. [77] Although studies with rhesus monkeys showed
unencumbered entry into the brain [77], no human studies
have been reported to date.
4.3. 18F-THK523, 18F-THK5105, and 18F-THK5117
Quinoline and benzimidazole derivatives were identified
as candidates for tau imaging tracer by screening small mol-
ecules binding to b sheets [74,109,110]. A quinoline
derivative, THK523 (Fig. 1), was radiolabeled with 18F and
preclinically tested [73]. In vitro saturation binding studies
demonstrated that this tracer bound with higher affinity to
tau (Kd 5 1.67 nM) than to Ab fibrils (Kd 5 20.7 nM).
Although autoradiography analysis indicated that 18F-
THK523 bound selectively to PHF tau deposits at tracer con-
centrations [111], fluorescent studies showed that THK523
selectively binds to PHF tau and not Ab in AD brains, while
failing to bind to tau lesions in non-AD tauopathies or to a-
synuclein deposits in Parkinson’s disease brains [112].
Furthermore, 18F-THK523 can cross the BBB and success-
fully labeled tau protein deposits in the brain of a tau trans-Fig. 2. Autoradiographic studies of contiguous AD hemibrain sections with 18F-T
pattern of 18F-THK5105 and 11C-PiB, where 18F-THK5105 binding resembles tagenic mouse model [73]. First-in-human PET studies of
18F-THK523 were performed in AD patients and healthy
elderly controls [113]. To assess radiotracer selectivity to
tau over Ab, all participants also underwent a 11C-PiB PET
scans. Significantly higher 18F-THK523 retention was
observed in the lateral temporal, parietal, orbitofrontal, and
hippocampi of AD patients compared with age-matched
healthy controls, and 18F-THK523 retention was not associ-
ated with the retention of 11C-PiB, suggesting that in vivo
18F-THK523 binds selectively to tau and not to Ab. Further-
more, 18F-THK523 retention was correlated with cognitive
parameters, which is in agreement with postmortem studies
showing a strong association of neurofibrillary pathology
with dementia severity. Interestingly, in those healthy controls
with highAb burden as assessed by 11C-PiB, although cortical
18F-THK523 retentionwas low, 18F-THK523 retention in hip-
pocampus and insula was at the levels observed in AD
[113,114]. However, 18F-THK523 retention in gray matter
is relatively lower than that in white matter, which does not
allow clear visualization of the distribution of tau pathology
by visual inspection of PET images [113].
Through compound optimization process, novel 18F-
labeled 2-arylquinoline derivatives, 18F-THK5105 and 18F-
THK5117 (Fig. 1), were further developed [110]. In vitro
binding assays demonstrated higher binding affinity of
18F-THK5105 to synthetic tau fibrils (Kd 5 1.45 nM) than
to Ab1-42 fibrils (Kd 5 35.9 nM). In addition, both
18F-
THK5105 (Kd 5 2.63 nM) and
18F-THK5117
(Kd 5 5.19 nM) showed higher binding affinity for tau-
rich AD brain homogenates than 18F-THK523. In an autora-
diography analysis of AD brains, laminar distributions of
18F-THK5105 and 18F-THK5117 were observed in the
deep layer of temporal gray matter and coincided with
NFTs and neuropil threads [110]. Furthermore, the distribu-
tion of the binding of these tracers in AD brain sections was
completely different from that of 11C-PiB (Fig. 2). First-in-
human PET studies of 18F-THK5105 were performed in AD
patients and healthy elderly controls [115]. PET imagesHK5105, 11C-PiB, and tau immunostaining, showing the different binding
u immunostaining (modified from [110]).
Fig. 3. 18F-T807 autoradiography on brain sections from different groups and its comparison with paired helical filament (PHF) tau and amyloid-b (Ab) double
immunohistochemistry (IHC). 18F-T807 colocalized with PHF tau but not with Ab plaques. Low (top row) and high magnification from the framed areas (bot-
tom row). Images of PHF tau (left) and Ab (right) IHC double immunostaining and autoradiogram image (middle) from two adjacent sections (10 mm) from a
PHF tau–rich brain (frontal lobe). Positive 18F-T807 labeling colocalized with immunostaining of PHF tau but not with Ab plaques, as indicated by arrows.
Fluorescent and autoradiographic images were obtained using a Fujifilm FLA-7000 imaging instrument (Fuji Photo Film Co., Ltd. Tokyo, Japan). Scale
bars, 5 2 mm (Reproduced with permission from Alzheimer Dement [116]).
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jects. In AD patients, 18F-THK5105 retention was observed
in those brain areas, such as the mesial and lateral temporal
lobes, known to have high tau deposition. Similar to 18F-
THK523, 18F-THK5105 retention in AD patients was not
associated with 11C-PiB retention but was correlated with
dementia severity and brain atrophy [115]. First-in-human
PET studies with 18F-THK5117 are currently ongoing. Pre-
liminary data indicate a better pharmacokinetics and better
signal-to-noise ratios for 18F-THK5117 than 18F-THK5105.4.4. 18F-T807 and 18F-T808
Using in vitro autoradiography to screen and characterize
several novel benzimidazole pyrimidines derivatives [84],
two novel tracers were identified, 18F-T807 [116] and 18F-
T808 (Fig. 1), that bind with nanomolar affinity to PHF
tau, displaying more than a 25-fold selectivity for PHF tau
over Ab. (Fig. 3) First-in-human 18F-T807 PET studies in
AD patients, MCI, and healthy participants have shown
that cortical 18F-T807 retention follows the known distribu-
tion of PHF tau in the brain [76] where higher 18F-T807
cortical retention was significantly associated with
increasing disease severity, consistent with postmortem
studies showing the strong association of tau pathology
with severity of dementia [117]. In contrast to 18F-T807, hu-
man studies with 18F-T808 in three healthy controls and
eight AD patients showed better tracer kinetics than with
18F-T807, but substantial deflurination was observed in
some cases [118]. A PET-neuropathology correlation in
one of the AD patients who died 5 months after undergoing
a 18F-T808 PET scan showed that the postmortem fluores-
cent PHF tau staining was largely in agreement with the
observed in vivo 18F-T808 cortical retention in several brain
regions [119].4.5. 11C-PBB3
The latest entry in the roster of tau imaging agents is a 11C
tracer: 11C-PBB3 (Fig. 1) [120] based on a phenyl/pyridinyl-
butadienyl-benzothiazoles/benzothiazolium (PBB) scaffold.
These compounds are characterized by a p-electron conju-
gated backbone with a specific extent ranging from 13 to
19 A that apparently allows binding to a broad range of
AD and non-AD tau aggregates [120]. Several PBB candi-
dates underwent a thorough preclinical evaluation. Although
in vitro autoradiographic studies in AD brain sections
showed substantial nonselective binding to plaques and tan-
gles, two-photon laser scanning fluorescence microscopy
studies in a tau transgenic mouse model showed rapid clear-
ance of the tracer with selective binding to tau tangles.
Similar results were observed in micro-PET studies,
showing higher PBB3 binding in the spinal cord of the
same transgenic tau mouse model [120]. Preliminary clinical
studies in three healthy control volunteers and three AD pa-
tients assessed with both 11C-PBB3 and 11C-PiB showed a
different pattern of brain retention between the two tracers
suggesting that at high specific activities, 11C-PBB3 binds
selectively to tau, although marked retention of 11C-PBB3
in the venous sinuses was also observed [120]. A 11C-
PBB3 PET study in a patient diagnosed with CBD showed
tracer retention in the basal ganglia region, suggesting
11C-PBB3 might bind other non-AD tau conformations.5. Conclusions
Imaging of tau pathology will allow a more profound
insight into tau deposition in vivo, facilitating research
into the causes, diagnosis, and treatment of major neurode-
generative conditions such as AD, CTE or some variants
of FTLD, in which tau plays a role. Although the underlying
mechanism remains unknown, CTE and traumatic brain
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development of AD [16,121]. Does TBI accelerate the
development of Ab pathology, of misfolded tau, or of
both? [17,121,122] TBI is a growing problem in both
military and civilian populations, and the availability
of selective tau tracers to measure tau pathology in
humans will help to provide insights concerning the
pathophysiology of TBI and CTE. The development of
selective tau tracers will allow not only the in vivo
assessment of regional tau burden in the brain of AD
patients but also a means to evaluate its relation to Ab
deposition [73,76,123–125]. By allowing assessment of the
time course of tau accumulation to be correlated with
current cognitive impairment and predict cognitive
decline, it will assist in the evaluation of the neurobiology
of AD and non-AD tauopathies. In conjunction with Ab im-
aging, it will improve the specificity of diagnosis and allow
for early detection of tau pathology in those individuals
deemed at risk of developing AD or CTE.
The development of selective tau radiotracers is faced
with several challenges [59]. From a tracer development
perspective, a candidate radiotracer should be amenable
for high specific activity labeling with 18F or other long-
lived radioisotopes to allow a more cost-effective and wider
application of the technique. These tracers should be lipo-
philic, nontoxic, small molecules with a high selectivity
for tau, preferably with no radiolabeled metabolites that
enter the brain. The current research indicates that the design
of tau radioligands with nanomolar or subnanomolar affinity
for tau with an appropriate lipophilicity is feasible
[73,74,77,116,120]. Although nanomolar or subnanomolar
affinity for tau is desirable for selectivity and to provide an
adequate signal-to-noise ratio, it might also delay reaching
steady state, therefore requiring prolonged scanning times.
By the same token, although lipophilicity is necessary for
the tracer to penetrate the BBB, high lipophilicity might
lead to high nonspecific binding and a reduction of the
signal-to-noise ratio [68,69].
There are also challenges associated with the idiosyn-
crasies of tau deposition [59]. For example, in AD, a tau
radiotracer needs to be highly selective to overcome higher
Ab concentrations. Even more relevant, different conforma-
tions of the tau aggregates, either due to specific tau isoforms
or different posttranslational modifications, might prevent
the development of a “universal” tau radiotracer that will
recognize all types of tau pathologies. As with Ab [126],
the polymorphism of tau aggregates might affect tracer bind-
ing, where a radiotracer that is able to identify PHF taumight
not be able to bind, or bind with the same affinity, to other
known ultrastructural conformations of tau. This is evident
in some Ab imaging reports in which in some cases of famil-
ial autosomal dominant forms of AD [127,128] or early
stages of Ab deposition [129], lacking the typical fibrillar
Ab conformation seen in sporadic AD, there was little PiB
retention. Moreover, although Ab’s amino acid sequence
in human and nonhuman primates is identical, nonhumanprimates do not develop the full AD phenotype, and most
importantly, the Ab plaques do not bind PiB [130]. This il-
lustrates the critical role of fibril polymorphism in regards
to tracer binding.
Therapies targeting irreversible neurodegenerative pro-
cess have a better chance to succeed if applied early. There-
fore, early detection of the underlying pathologic process is
likely to be critical for therapeutic trials aimed at modulating
PHF tau [87,131,132]. Tau imaging, by quantifying tau
burden in living patients will allow improved selection of
those individuals most likely to benefit from disease-
modifying therapy, as well as longitudinal patient moni-
toring and assessment of efficacy, to properly evaluate
whether the treatment response is related to a slowdown or
reduction in tau deposition.
There is an increasing body of research focused on the
development of tau radiotracers that is allowing to establish
which radiotracer characteristics are relevant for selective
and specific binding to tau deposits in the brain. There is still
much to be done. Development of new leads and new and
improved radiotracers will be decisive for further progress
in the field. The inception of new tau imaging tracers will
make possible a more precise characterization of the role
of tau deposits in TBI and neurodegenerative conditions,
potentially allowing development and assessment of
disease-specific therapeutics that will delay or prevent the
onset of cognitive impairment among the civilian population
and injured military personnel returning from the battlefield.Acknowledgments
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